bioAffinity Technologies, Inc. (BIAF) AI Stock Analysis

bioAffinity Technologies, Inc. is a pioneering biotechnology firm focused on advancing non-invasive diagnostic tests and specialized cancer treatments. Founded in 2014 and headquartered in San Antonio, Texas, the company is dedicated to developing innovative solutions that improve early detection and treatment outcomes in cancer patients. At the forefront of its offerings is CyPath lung, a diagnostic test specifically designed for the early detection of lung cancer to enable timely intervention. In addition to diagnostics, bioAffinity Technologies engages in research to develop targeted therapies that address cancer at the cellular level by integrating scientific research with practical diagnostic tools.

bioAffinity experienced substantial revenue expansion between FY2021 and FY2024, rising from $1,306 to $9.4M, before revenue dropped 34.2% to $6.2M in FY2025. Across four years, its revenue CAGR reached 728.8%. Gross margin compressed to 23.2% in FY2025 from 36.1% in FY2024. Profitability remains deeply negative, with FY2025 net income of -$14.9M and an operating margin of -171.6%. Research and development expenses grew to $2.1M in FY2025 from $1.1M in FY2021. For the latest quarter ended June 30, 2026, quarterly revenue grew 19.0% year-over-year, while trailing twelve month revenue stood at $5.9M with a net profit margin of -257.3%.

As of June 30, 2026, bioAffinity Technologies held $2.4M in cash and short-term investments against total debt of $1.4M, leaving net cash of $994,714. Total assets stood at $7.6M against shareholders' equity of $3.8M, with a current ratio of 1.44 and a debt-to-equity ratio of 0.38. The company burned cash in FY2025, reporting operating cash flow of -$9.3M, free cash flow of -$9.4M, and capital expenditures of $60,568. The five-year share count change was 5613.1%.

With a market cap of $4.8M and an enterprise value of $3.7M, BIAF trades at a price-to-sales multiple of 0.8x and an EV-to-revenue multiple of 0.6x, compared to the median of 4.1x price-to-sales for its US-listed Healthcare peers. Its price-to-book ratio is 1.3x. Over the past year, BIAF shares fell 92.7%, while the S&P 500 (SPY) returned 16.8%. The stock traded at $3.73 on October 16, 2026, which is 81.4% below its 200-day average and near its 52-week low of $3.23.

One analyst covers bioAffinity Technologies with a mean price target of $6.00, representing a 60.9% upside compared to the last close of $3.73. For the next fiscal year, the analyst estimates revenue of $7.3M, reflecting revenue growth of 20.0%, and an EPS estimate of -$8.10, representing an EPS growth estimate of 43.8%. The company beat EPS estimates in 1 of the last 4 quarters. The next earnings date is November 13, 2026.

This page is an AI-written research summary of bioAffinity Technologies, Inc. (BIAF). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BIAF income statement, BIAF balance sheet, BIAF key metrics, BIAF analyst forecast, BIAF chart. See the BIAF stock overview for the latest quote and news.